AXIM (AXIM Biotechnologies) Shares Buyback Ratio %: -13.07 (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is AXIM Biotechnologies Shares Buyback Ratio %?

AXIM Biotechnologies AXIM +1.36% Shares Buyback Ratio % is -13.07 as of Jul. 23, 2026.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. AXIM Biotechnologies's current shares buyback ratio was -13.07%.

AXIM Biotechnologies Shares Buyback Ratio % Related Terms

AXIM Biotechnologies Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for AXIM Biotechnologies's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies Shares Buyback Ratio % Chart

AXIM Biotechnologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -93.24 -10.19 -39.35 -27.79 -29.67

AXIM Biotechnologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.22 -5.76 -8.30 -4.35 -0.06

AXIM Biotechnologies Shares Buyback Ratio % Calculation

AXIM Biotechnologies's Shares Buyback Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2023 ) - Shares Outstanding (EOP) (A: Dec. 2024 )) / Shares Outstanding (EOP) (A: Dec. 2023 )
=(245.929 - 318.895) / 245.929
=-29.67%

AXIM Biotechnologies's Shares Buyback Ratio for the quarter that ended in Jun. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2025 ) - Shares Outstanding (EOP) (A: Jun. 2025 )) / Shares Outstanding (EOP) (A: Mar. 2025 )
=(332.761 - 332.957) / 332.761
=-0.06%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -13.07 mean?
AXIM Biotechnologies (AXIM) has a Shares Buyback Ratio % of -13.07 as of Jul. 23, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on AXIM Biotechnologies and its competitors.
Is AXIM Biotechnologies' Shares Buyback Ratio % too high?
AXIM Biotechnologies' current Shares Buyback Ratio % is -13.07.
How does AXIM Biotechnologies' Shares Buyback Ratio % compare to ZVSA and HEPA?
AXIM Biotechnologies' Shares Buyback Ratio % of -13.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on AXIM Biotechnologies and its competitors. AXIM Biotechnologies's current Shares Buyback Ratio % is -13.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Shares Buyback Ratio % of -13.07. The current Shares Buyback Ratio % is -13.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Shares Buyback Ratio % is -13.07 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.